Form 4: Tarsus Pharmaceuticals Director Receives Stock Options and RSUs

Tarsus Pharmaceuticals, Inc. reports that Director Scott W. Morrison was granted stock options and restricted stock units on June 25, 2026.

Summary

• Director Scott W. Morrison received a grant of stock options and Restricted Stock Units (RSUs) on June 25, 2026.
• The stock option is for 3,837 shares with an exercise price of $64.34 and is set to expire on June 24, 2036.
• The RSUs are for 2,417 shares of common stock.
• Both the stock options and RSUs vest in full on the one-year anniversary of the grant date, provided the director maintains continuous service.
• These grants are in connection with Morrison's service as a non-employee director as of the Company's 2026 annual meeting of stockholders.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents routine compensation for a director and does not contain new financial performance data or strategic shifts.

Positives

• Grant of equity awards (stock options and RSUs) to a director, indicating continued engagement and alignment with the company's performance.
• The stock options have a long expiration date (June 24, 2036), providing a significant potential upside over time.
• Vesting schedule tied to continuous service aligns director incentives with long-term company success.

Risks

• The value of the stock options and RSUs is subject to the future performance of Tarsus Pharmaceuticals' stock price.
• Vesting is contingent on continuous service, meaning the director could forfeit unvested awards if service is terminated before the vesting date.

Future Outlook

The future outlook for the granted stock options and RSUs is dependent on the company's stock performance and the director's continued service. The options have a long-term expiration, suggesting a belief in potential future value appreciation.

Industry Context

StockSavvy.ai notes that the issuance of stock options and RSUs to non-employee directors is a standard practice in the pharmaceutical and biotechnology sectors to attract and retain experienced leadership and align their interests with shareholders.

Stakeholder Impact

• Shareholders: The issuance of equity awards to directors is a common form of compensation that aligns director interests with shareholder value. The long-term nature of the options suggests management's confidence in future stock appreciation.
• Employees: This filing does not directly impact employees, but it reflects standard compensation practices for board members.
• Management: The grant reinforces the compensation structure for non-employee directors.

Next Steps

• Director Scott W. Morrison is expected to maintain continuous service to ensure the vesting of stock options and RSUs.
• The company will continue to monitor the performance of its stock to determine the ultimate value of these awards.

Key Dates

Keywords

Form 4, SEC Filing, Tarsus Pharmaceuticals, Scott W. Morrison, Director Compensation, Stock Options, Restricted Stock Units, Equity Awards, Beneficial Ownership